NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SCYX
SCYNEXIS, Inc.
There isn't enough reported data to score SCYX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SCYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
SCYX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SCYX PE Valuation
SCYX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SCYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SCYX's losses to grow, with revenue declining.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SCYX on earnings quality, reporting a profit while its opponent remains loss making.
SCYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$2.64 |
| Q2 2026 | -$2.09 | +$1.11 |
| Q1 2026 | -$3.84 | +$0.64 |
| Q4 2025 | -$1.36 | +$2.16 |
| Q3 2025 | -$4.08 | +$1.28 |
| Q2 2025 | -$3.20 | +$2.00 |
| Q1 2025 | -$4.48 | -127% |
| Q4 2024 | -$3.52 | -132% |
SCYX is still losing money, but far less than before: $1.44 per share over the past year, against $76.62 at its worst in late 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SCYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SCYX on profitability, with a higher operating margin.
SCYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $235K | -83% |
| Q4 2025 | $18.6M | +1808% |
| Q3 2025 | $334K | -49% |
| Q2 2025 | $1.4M | +85% |
| Q1 2025 | $257K | -81% |
| Q4 2024 | $977K | -83% |
| Q3 2024 | $660K | -63% |
| Q2 2024 | $736K | -99% |
SCYX's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3309% | -2608 points |
| Q4 2025 | 56% | +881 points |
| Q3 2025 | -2516% | -953 points |
| Q2 2025 | -701% | +554 points |
| Q1 2025 | -3350% | -2658 points |
| Q4 2024 | -824% | -426 points |
| Q3 2024 | -1564% | -990 points |
| Q2 2024 | -1255% | -1344 points |
SCYX's operating margin was −3309% last quarter, up 42 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SCYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
SCYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5M | +$1.3M |
| Q2 2026 | -$14.9M | -$7.4M |
| Q1 2026 | -$8.1M | -$636K |
| Q4 2025 | $18.4M | +$28.3M |
| Q3 2025 | -$8.7M | -1240% |
| Q2 2025 | -$7.5M | +$3.4M |
| Q1 2025 | -$7.5M | -$3.5M |
| Q4 2024 | -$9.9M | -$2.2M |
SCYX has burned cash in almost every quarter: −$12M over the past year, against −$34M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SCYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SCYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18.8K shares |
| 1 year | +90% | +5.6M shares |
| 3 years | +90% | +5.6M shares |
| 5 years | +257% | +8.5M shares |
SCYX has 12M diluted shares, up 90% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SCYX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.6x | Net Cash |
| Q2 2023 | -0.9x | Net Cash |
SCYX has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SCYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 6.3 | Oversold |
SCYX's weekly RSI is 36 (neutral) and its Stochastic is 6 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SCYX PE vs Healthcare Sector
| Metric | SCYX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCYX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SCYX on trend strength, trading above more of its moving averages.
SCYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.96 | 16% below |
| 20 week MA | $4.44 | 25% below |
| 50 week MA | $5.40 | 38% below |
| 100 week MA | $6.29 | 47% below |
| 200 week MA | $11.4 | 71% below |
SCYX is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SCYX on returns for 2026, with the stronger performance.
SCYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.8 | $57.1 | -18% |
| 2021 | $57.1 | $54.0 | -5.5% |
| 2022 | $54.0 | $12.5 | -77% |
| 2023 | $12.5 | $17.8 | +43% |
| 2024 | $17.8 | $7.99 | -55% |
| 2025 | $7.99 | $4.70 | -41% |
| 2026 YTD | $4.70 | $3.33 | -29% |
SCYX has finished lower in five of the last six years. It's down 29% so far in 2026.